Skip to main content

InnoCare Approved to Launch BTK Inhibitor for Three Indications in China

Beijing InnoCare Pharma reported China 's NMPA approved its BTK inhibitor for three indications: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). All three indications are for patients who have relapsed or refractory forms of the disease. Orelabrutinib will be the first InnoCare candidate to be commercialized. Earlier this year, InnoCare completed a $288 million IPO in Hong Kong that valued the company at $1 billion. More details.... Stock Symbol: (HK: 09969) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.